Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies

Blood Cancer Discov. 2023 May 1;4(3):172-175. doi: 10.1158/2643-3230.BCD-22-0213.

Abstract

In patients with multiple myeloma, completion of mRNA-based vaccination schemes failed to yield detectable SARS-CoV-2 Omicron-neutralizing antibodies and S1-RBD-specific CD8+ T cells in approximately 60% and 80% of the cases, respectively. Patients who develop breakthrough infections exhibited very low levels of live-virus neutralizing antibodies and the absence of follicular T helper cells. See related article by Azeem et al., p. 106 (9). See related article by Chang et al., p. 1684 (10).

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Neutralizing
  • Breakthrough Infections
  • CD8-Positive T-Lymphocytes
  • COVID-19* / prevention & control
  • Hematologic Neoplasms*
  • Humans
  • Multiple Myeloma*
  • SARS-CoV-2 / genetics
  • mRNA Vaccines

Substances

  • mRNA Vaccines
  • Antibodies, Neutralizing

Supplementary concepts

  • SARS-CoV-2 variants